- Home
- / Autifony Therapeutics
Autifony Therapeutics
Total Funding
$24.2 M
Revenue
£22.8 M
FY, 2018
Autifony Therapeutics Summary
Company Summary
- Overview
- Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system. It specializes in researching treatments for hearing disorders, tinnitus, age-related hearing loss, and schizophrenia.
- Type
- Private
- Status
- Active
- Founded
- 2011
- HQ
- Stevenage, GB | view all locations
- Website
- https://autifony.com
- Cybersecurity rating
Table of Contents
Key People
Giuseppe S. Alvaro, Founder and Chief Research Officer
Barbara Domayne-Hayman, Chief Business Officer
Daniel Umbricht, Chief Medical Officer
LocationsView all
2 locations detected
Stevenage, England HQ
United Kingdom
Gunnels Wood Rd
Padova, Veneto
Italy
Corso Stati Uniti, 4f
Autifony Therapeutics Financials
Summary Financials
- Revenue (FY, 2018)
- £22.8M
- Net income (FY, 2018)
- £16.2M
- Cash (FY, 2018)
- £19.4M
- EBIT (FY, 2018)
- £16.2M